Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
abatement, accredited, acetate, affirm, Alameda, alanine, alia, ALK, Allergan, alongside, alpha, ALT, alteration, aminotransferase, amylase, anticancer, APC, appraisal, aseptic, aspartate, AST, Astra, audience, auditor, AVEO, ballot, Bay, bill, biotech, blinded, bona, bridging, Brown, Cadillac, caliber, Casein, catenin, censoring, cetuximab, charitable, circumvent, cobimentinib, complement, compliant, concept, construction, context, Coordination, count, DCR, Decentralised, defray, degradation, DOR, dossier, draft, drawn, DTC, ductal, durable, durvalumab, endocrine, epacadostat, esaxerenone, esophagobronchial, etiology, evidenced, Exploratory, extrahepatic, fide, fistula, forthcoming, furniture, GDPR, genetic, Governor, GSK, head, heading, hepatorenal, highest, histology, Holdco, hypokalemia, IM, image, impede, imposition, inappropriate, Incyte, indefinitely, infusion, inoperable, instability, instance, introduce, introducing, inverse, Jerry, Justice, justification, Leasehold, led, legislature, licensor, lymphocyte, macrovascular, monoclonal, Multidisciplinary, myeloma, neck, neutrophil, nonstatutory, offshore, Ohio, operationally, panitumumab, Parkway, payoff, PCAOB, platelet, portal, prevailing, pulmonary, pursuit, radiographic, Reauthorization, reauthorize, reliant, relocate, relocation, repatriated, resold, safeguard, savolitinib, sBLA, scrutinize, Senate, Shield, smaller, soft, StemSynergy, streamline, Taihio, technique, tipiracil, tissue, tivozanib, transatlantic, transferee, translated, tremelimumab, trifluridine, turnover, UC, UK, umbrella, unascertainable, unasserted, unavailable, uncollectible, underway, unused, upper, ureter, urge, urinary, variation, vein, verify, vigorously, wild, Wnt, Zeneca
Removed:
accreted, accretion, accuse, AMG, Ariad, ArQule, assumed, attributable, bad, balloon, bearing, beneficially, cap, cGMP, close, COMET, concentrated, continuance, convert, creditworthy, cure, declare, declaring, dedicating, dedication, default, deprioritized, derive, destroyed, deterioration, diagnosed, dilution, disadvantage, dispense, dividing, emerged, employing, exceeded, exercisable, extremely, flexibility, forfeiture, fulfillment, GCP, immunodeficiency, imprisonment, inconvenient, incremental, incumbent, incurrence, inhibition, ipilumumab, lapse, largely, leverage, leveraged, lieu, long, LXR, mCRPC, misuse, molecularly, negligence, negotiated, noncancelable, notify, NPU, ocular, pediatric, planning, plant, pool, popular, postmarketing, preceding, prednisone, predominantly, premium, prepay, prioritization, prioritize, promptly, radioactive, ready, reliably, relieve, remote, removing, rendered, renewal, rental, reportable, resale, revaluation, reversal, shipment, simplified, Sobi, subleased, Subtopic, summarize, summarized, takeover, tier, tivantinib, trait, treasury, typical, unsecured, unsolicited, utility, violate, vulnerability, warehouse, workforce
Filing tables
Filing exhibits
- 10-K Annual report
- 10.20 Exhibit 10.20
- 10.21 Exhibit 10.21
- 10.22 Exhibit 10.22
- 10.23 Exhibit 10.23
- 10.24 Exhibit 10.24
- 10.25 Exhibit 10.25
- 10.35 Exhibit 10.35
- 10.39 Exhibit 10.39
- 10.46 Exhibit 10.46
- 10.48 Exhibit 10.48
- 12.1 Exhibit 12.1
- 21.1 Exhibit 21.1
- 23.1 Exhibit 23.1
- 31.1 Exhibit 31.1
- 31.2 Exhibit 31.2
- 32.1 Exhibit 32.1
- Download Excel data file
- View Excel data file
Related press release
Associated EXEL transcripts
EXEL similar filings
Filing view
External links
Exhibit 12.1
EXELIXIS, INC.
STATEMENT RE COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
(in thousands)
Our earnings were insufficient to cover fixed charges for the periods presented except for the year ended December 31, 2017. The following table sets forth our ratio of earnings to fixed charges for the year ended December 31, 2017 and our deficiency of earnings to cover fixed charges for the other periods presented.
Year Ended December 31, | |||||||||||||||||||
2017 | 2016 | 2015 | 2014 | 2013 | |||||||||||||||
Fixed charges: | |||||||||||||||||||
Interest expense | $ | 8,679 | $ | 33,060 | $ | 40,680 | $ | 41,362 | $ | 38,779 | |||||||||
Interest portion of rental expense | 592 | 721 | 755 | 886 | 935 | ||||||||||||||
Total fixed charges | $ | 9,271 | $ | 33,781 | $ | 41,435 | $ | 42,248 | $ | 39,714 | |||||||||
Earnings available for fixed charges: | |||||||||||||||||||
Net income (loss) before income taxes | $ | 158,577 | $ | (70,222 | ) | $ | (161,744 | ) | $ | (261,297 | ) | $ | (238,192 | ) | |||||
Fixed charges per above | 9,271 | 33,781 | 41,435 | 42,248 | 39,714 | ||||||||||||||
Total earnings available for fixed charges | $ | 167,848 | $ | (36,441 | ) | $ | (120,309 | ) | $ | (219,049 | ) | $ | (198,478 | ) | |||||
Ratio of earnings to fixed charges | 18.10 | N/A | N/A | N/A | N/A | ||||||||||||||
Deficiency of earnings available to cover fixed charges | N/A | $ | (70,222 | ) | $ | (161,744 | ) | $ | (261,297 | ) | $ | (238,192 | ) |